Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data

Computer Methods and Programs in Biomedicine

Volumn 91, Issue 2, 2008, Pages 91-99

  Lin, Chao Cheng ^a,b   Wang, Ying Chieh ^c   Chen, Jen Yeu ^c   Liou, Ying Jay ^d   Bai, Ya Mei ^d,e   Lai, I Ching ^c   Chen, Tzu Ting ^c   Chiu, Hung Wen ^f   Li, Yu Chuan ^e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clozapine; Genetic polymorphism; Neural network models; Schizophrenia

Indexed keywords

DRUG PRODUCTS; GENETIC ENGINEERING; MATHEMATICAL MODELS; MEDICAL PROBLEMS; POLYMORPHISM;

CLOZAPINE; GENETIC POLYMORPHISM; NEURAL NETWORK MODELS; SCHIZOPHRENIA;

NEURAL NETWORKS;

CLOZAPINE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERCEPTRON; PHARMACOGENETICS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; STATISTICAL MODEL; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMPUTER SIMULATION; DECISION SUPPORT SYSTEMS, CLINICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEURAL NETWORKS (COMPUTER); OUTCOME ASSESSMENT (HEALTH CARE); PATTERN RECOGNITION, AUTOMATED; PHARMACOGENETICS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 44949169359     PISSN: 01692607     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmpb.2008.02.004     Document Type: Article

References (46)

1. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
2. Fleishman M. The schizophrenia algorithm. Psychiatr. Serv. 50 (1999) 703-704
3. Wahlbeck K., Cheine M., and Essali M.A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane. Database. Syst. Rev. 4 (1999) 10.1002/14651858.CD000059 Art. No.: CD000059
4. Chiles J.A., Miller A.L., Crismon M.L., Rush A.J., Krasnoff A.S., and Shon S.S. The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. Psychiatr. Serv. 50 (1999) 69-74
5. Lin C.C., Bai Y.M., Chen J.Y., Lin C.Y., and Lan T.H. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr. Scand. 100 (1999) 158-161
6. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
7. Pisani F., Oteri G., Costa C., Di Raimondo G., and Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 25 (2002) 91-110
8. Arranz M.J., Munro J., Sham P., Kirov G., Murray R.M., Collier D.A., and Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 32 (1998) 93-99
9. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., Lesch K.P., Meyer J.F., Sham P., Collier D.A., Murray R.M., and Kerwin R.W. Pharmacogenetic prediction of clozapine response. Lancet 355 (2000) 1615-1616
10. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., and Carpenter Jr. W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155 (1998) 751-760
11. Hong C.J., Yu Y.W., Lin C.H., Cheng C.Y., and Tsai S.J. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr. Genet. 11 (2001) 219-222
12. Honigfeld G., and Patin J. Predictors of response to clozapine therapy. Psychopharmacology (Berl) 99 Suppl. (1989) S64-S67
13. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., and Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 151 (1994) 1744-1752
14. Malhotra A.K., Goldman D., Ozaki N., Breier A., Buchanan R., and Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 153 (1996) 1092-1094
15. Masellis M., Paterson A.D., Badri F., Lieberman J.A., Meltzer H.Y., Cavazzoni P., and Kennedy J.L. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 346 (1995) 1108
16. Nothen M.M., Rietschel M., Erdmann J., Oberlander H., Moller H.J., Nober D., and Propping P. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 346 (1995) 908-909
17. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., and Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49 (1992) 345-353
18. Rosenheck R., Lawson W., Crayton J., Cramer J., Xu W., Thomas J., Stolar M., and Charney D. Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. Biol. Psychiatry 44 (1998) 475-482
19. Shaikh S., Collier D., Arranz M., Ball D., Gill M., and Kerwin R. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343 (1994) 1045-1046
20. Sodhi M.S., Arranz M.J., Curtis D., Ball D.M., Sham P., Roberts G.W., Price J., Collier D.A., and Kerwin R.W. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7 (1995) 169-172
21. Tsai S.J., Wang Y.C., Yu Younger W.Y., Lin C.H., Yang K.H., and Hong C.J. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr. Res. 49 (2001) 53-58
22. Umbricht D.S., Wirshing W.C., Wirshing D.A., McMeniman M., Schooler N.R., Marder S.R., and Kane J.M. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J. Clin. Psychiatry 63 (2002) 420-424
23. Arranz M.J., and Kerwin R.W. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann. Med. 32 (2000) 128-133
24. Subasi A., and Ercelebi E. Classification of EEG signals using neural network and logistic regression. Comput. Methods Programs Biomed. 78 (2005) 87-99
25. Delen D., Walker G., and Kadam A. Predicting breast cancer survivability: a comparison of three data mining methods. Artif. Intell. Med. 34 (2005) 113-127
26. Bai Y.M., Lin C.C., Chen J.Y., and Lin C.Y. Weight gain among patients on clozapine. Psychiatr. Serv. 50 (1999) 704-705
27. Hsu J.W., Wang Y.C., Lin C.C., Bai Y.M., Chen J.Y., Chiu H.J., Tsai S.J., and Hong C.J. No evidence for association of alpha 1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence. Neuropsychobiology 42 (2000) 62-65
28. Shannon C.E., and Weaver W. The Mathematical Theory of Communication (1949), University of Illinois Press, Urbana, IL
29. Tourassi G.D., and Floyd C.E. The effect of data sampling on the performance evaluation of artificial neural networks in medical diagnosis. Med. Decis. Making 17 (1997) 186-192
30. Miller A.S., Blott B.H., and Hames T.K. Review of neural network applications in medical imaging and signal processing. Med. Biol. Eng. Comput. 30 (1992) 449-464
31. Penny W., and Frost D. Neural networks in clinical medicine. Med. Decis. Making 16 (1996) 386-398
32. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
33. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
34. Arana E., Marti-Bonmati L., Paredes R., and Bautista D. Focal calvarial bone lesions. Comparison of logistic regression and neural network models. Invest. Radiol. 33 (1998) 738-745
35. Tu J.V. Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. J. Clin. Epidemiol. 49 (1996) 1225-1231
36. Natt N.K., Kaur H., and Raghava G.P. Prediction of transmembrane regions of beta-barrel proteins using ANN- and SVM-based methods. Proteins 56 (2004) 11-18
37. Miller A.L., Crismon M.L., Rush A.J., Chiles J., Kashner T.M., Toprac M., Carmody T., Biggs M., Shores-Wilson K., Chiles J., Witte B., Bow-Thomas C., Velligan D.I., Trivedi M., Suppes T., and Shon S. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr. Bull. 30 (2004) 627-647
38. Royal Australian, New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia, Related, Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust. N. Z. J. Psychiatry 39 (2005) 1-30
39. Politi E., Franchini L., Spagnolo C., Smeraldi E., and Bellodi L. Supporting tools in psychiatric treatment decision-making: sertraline outcome investigation with artificial neural network method. Psychiatry Res. 134 (2005) 181-189
40. Franchini L., Spagnolo C., Rossini D., Smeraldi E., Bellodi L., and Politi E. A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Artif. Intell. Med. 23 (2001) 239-248
41. Serretti A., and Smeraldi E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med. Genet. 5 (2004) 27
42. Azuaje F. Genomic data sampling and its effect on classification performance assessment. BMC Bioinform. 4 (2003) 5
43. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) 106S-115S
44. Gerlach J., and Peacock L. New antipsychotics: the present status. Int. Clin. Psychopharmacol. 10 Suppl. 3 (1995) 39-48
45. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., and Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99 Suppl. (1989) S68-S72
46. Haydon G.H., Jalan R., la-Korpela M., Hiltunen Y., Hanley J., Jarvis L.M., Ludlum C.A., and Hayes P.C. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J. Viral Hepat. 5 (1998) 255-264